Pharvaris' stock jumps on pivotal success in rare genetic disease

Data Readoutpositivedeucrictibant extended-releasePositive

AI Analysis

Summary

Pharvaris reported pivotal trial success for an extended-release once-daily formulation of deucrictibant, achieving injectable-like efficacy in treating a rare genetic disease characterized by swelling attacks.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Achieved injectable-like efficacy in once-daily pill formulation in pivotal trial

Importance:7/10

Sentiment:

0.80

rare_diseasegenetic_diseaseoral_formulationpivotal_datastock_movement

Related Companies

$PHVS

Read the original article

Published by Endpoints News on September 8, 2026 6:29 PM

Read Original